Surface Oncology Inc

Surface Oncology, Inc. operates as a clinical-stage immuno-oncology company. It focuses on biological pathways critical to the immunosuppressive tumor microenvironment and the development of next-generation cancer therapies. The firm’s pipeline includes wholly-owned lead programs targeting CD39 (SRF617) and IL-27 (SRF388), as well as a preclinical program focused on depleting tumor regulatory T cells via targeting CCR8 (SRF114). Its pipeline also includes licensed product programs, such as a collaboration with Novartis targeting CD73 (NZV930, Phase 1) and a collaboration with GlaxoSmithKline targeting PVRIG (SRF813, preclinical). The company was founded by David S. Grayzel in 2014 and is headquartered in Cambridge, MA.

Earnings data Q2 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Surface Oncology was created to advance next-generation approaches to cancer immunotherapy based on proprietary insights about novel immunotherapy targets and emerging areas of cancer immuno-biology. Together with world-leading scientific founders, the Company is advancing multiple preclinical programs that target novel mechanisms shown to play vital roles in tumor immune evasion.

CAMBRIDGE, Mass., April 19, 2021 (GLOBE NEWSWIRE) -- Surface Oncology, a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that it has been recognized by the Boston Business Journal as one of the Best Places to Work in 2021. This exclusive distinction features Massachusetts companies that have built outstanding work environments.

Surface Oncology Named a 2021 Best Places to Work Company by Boston Business Journal

CAMBRIDGE, Mass., April 09, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, will present preclinical findings supporting the company's lead product programs, SRF388 (targeting IL-27) and SRF617 (targeting CD39). These data will be presented as part of the American Association for Cancer Research (AACR) 2021 Annual Meeting, which is being held virtually April 10-15 and May 17-21, 2021.

Surface Oncology Presents Promising Preclinical Data for Lead Immunotherapy Product Candidates at the American Association for Cancer Research Annual Meeting

The company received an orphan drug designation from the FDA for one of its lead pipeline candidates.

Why Surface Oncology Stock Is Soaring Today

The stock price of Surface Oncology (Nasdaq: SURF) increased by over 16% during intraday trading. This is why it happened.

SURF Stock Price Increased Over 16% Intraday: Why It Happened

Shares of Surface Oncology Inc. (NASDAQ: SURF), a clinical-stage biopharma company, gained more than 19% in the extended session on Tuesday. What Happened: The spike in shares came after the Cambridge, Massachusetts-based company said Tuesday that one of its lead therapeutic candidates, SRF617, has received Orphan Drug Designation from the U.S. Food and Drug Administration for the treatment of patients with pancreatic cancer.

Why Surface Oncology Shares Spiked 19% Today

Its pancreatic cancer drug gets a nod from the FDA.

Why Surface Oncology Is Flying Higher After Hours Today

CAMBRIDGE, Mass., March 30, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for one of the company's lead therapeutic candidates, SRF617, for the treatment of patients with pancreatic cancer.

Surface Oncology's SRF617 Receives Orphan Drug Designation from FDA for Treatment of Pancreatic Cancer

3D Systems

Komatsu Ltd

Taiwan Semiconductor Manufacturing

Every night, Cathie Wood's Ark Investment Management sends out an email listing the stocks that were bought or sold by the firm's ETFs that day. In recent months, the emails have been known to cause certain stocks to see a spike in the after-hours session.

TSMC, BYD, Komatsu, Surface Oncology And 3D Systems — What Cathie Wood's Ark Bought And Sold Today

Biogen

D.R. Horton

Turtle Beach

Seneca Foods

Oppenheimer Holdings

It's been a long time coming, but the great value comeback appears to be underway.

6 Stocks to Play the Value Revival

CAMBRIDGE, Mass., March 10, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced two scientific e-posters sharing updated preclinical data will be presented at the American Association for Cancer Research (AACR) 2021 Annual Meeting, to be held virtually April 10-15 and May 17-21, 2021.

Surface Oncology to Present Preclinical Data for Lead Product Programs at the American Association for Cancer Research Annual Meeting

AnPac Bio-Medical Science Co

CorMedix

AnPac Bio-Medical Science Co., Ltd. (NASDAQ: ANPC), Surface Oncology, Inc. (NASDAQ: SURF) and CorMedix Inc. (NASDAQ: CRMD) are among the biggest movers among health care stocks Tuesday.

Why AnPac Bio-Medical, Surface Oncology, CorMedix Are Rallying Today

Surface Oncology Inc (NASDAQ: SURF) has entered into a clinical trial collaboration with Merck & Co (NYSE: MRK) to evaluate Surface's SRF388 with the latter's Keytruda (pembrolizumab). This combination will be studied as a component of the Phase 1 study of SRF388.

Surface Oncology To Test SRF388 Plus Keytruda Combo In Solid Tumor Settings

Surface Oncology, Inc. (SURF) delivered earnings and revenue surprises of 345.71% and 3.02%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Surface Oncology, Inc. (SURF) Q4 Earnings and Revenues Beat Estimates

The stock price of Surface Oncology Inc (NASDAQ: SURF) is trading at over 15% pre-market. This is why it happened.

SURF Stock Price Increases Over 15% Pre-Market: Why It Happened

Surface Oncology (SURF) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock

Surface Oncology (SURF) is Oversold: Can It Recover?

New Collaboration with Merck Will Evaluate SRF388, Targeting IL-27, in Combination with KEYTRUDA® (pembrolizumab) in Patients with Solid Tumors

Surface Oncology Reports Financial Results and Corporate Highlights for Fourth Quarter and Full Year 2020

Surface Oncology (SURF) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Should You Buy Surface Oncology (SURF) Ahead of Earnings?

Surface Oncology, Inc. (SURF) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Surface Oncology, Inc. (SURF) to Report Q4 Results: Wall Street Expects Earnings Growth

CAMBRIDGE, Mass., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation therapies targeting the tumor microenvironment, today announced that Rob Ross, M.D., incoming chief executive officer, will participate in the following virtual investor conferences:

Surface Oncology to Participate in Upcoming March Investor Conferences

The stock price of Surface Oncology Inc (NASDAQ: SURF) increased by 12.33%. This is why it happened.

SURF Stock Price Increased 12.33%: Why It Happened

Experienced clinical development executive to succeed current CEO Jeff Goater, who will become Chairman of the Board

Surface Oncology to Appoint Robert Ross, M.D., as President and Chief Executive Officer

Jounce Therapeutics

These baby biotechs are itching to come out of their shells.

2 Biotech Stocks Poised to Soar in 2021

Investors need to pay close attention to Surface Oncology (SURF) stock based on the movements in the options market lately.

Are Options Traders Betting on a Big Move in Surface Oncology (SURF) Stock?

CAMBRIDGE, Mass., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Jeff Goater, chief executive officer, will participate in the upcoming H.C. Wainwright Bioconnect 2021 Conference, which will take place January 11–14.

Surface Oncology to Participate in H.C. Wainwright Bioconnect 2021 Conference

Surface Oncology, Inc. (SURF) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

News for Surface Oncology Inc Stock (SURF)